India Pharmas Seen Shifting From Infectious Diseases To Long-Term Chronic Ailments (India)
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical companies appear to be shifting their product-development emphasis away from infectious diseases and more toward treating chronic diseases. Cardiovascular and diabetes diseases are now seen as having the highest growth potential in a segment of ailments driven by increasing urbanization and aging populations. The most successful drugs in that category are expected to be those required for the rest of the patient's life. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.